Dr. Sabichi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1504 Taub Loop
Houston, TX 77030Phone+1 713-873-8890Fax+1 713-798-6677
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1987 - 1990
- University of Colorado School of Medicine Anschutz Medical CampusClass of 1987
Certifications & Licensure
- NY State Medical License 1988 - 2026
- TX State Medical License 1998 - 2026
- MD State Medical License 1990 - 2017
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 1998 Jul 30
- Celecoxib in Treating Patients With Bladder Cancer Start of enrollment: 2000 Jun 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsPhase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.Jan O Kemnade, Marcus Florez, Anita Sabichi, Jun Zhang, Pavan Jhaveri
Oral Oncology. 2023-10-01 - Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes.Ola Soliman, David C Wilde, Jan O Kemnade, Anita L Sabichi, George Chen
Laryngoscope Investigative Otolaryngology. 2023-08-01 - 12 citationsPersistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.Marcus A Florez, Jan O Kemnade, Nan Chen, Wendy Du, Anita L Sabichi
Cancer Research Communications. 2022-07-26
Press Mentions
- NMSU Alum, M.D. Anderson Cancer Researcher Creates ScholarshipNovember 22nd, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: